ViroPharma Stock Rating Lowered by Mizuho (VPHM)
ViroPharma (NASDAQ:VPHM) was downgraded by analysts at Mizuho from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. They currently have a $39.00 target price on the stock. Mizuho’s price objective would suggest a potential downside of 1.79% from the stock’s previous close. The analysts noted that the move was a valuation call.
A number of other firms have also recently commented on VPHM. Analysts at Zacks reiterated a “neutral” rating on shares of ViroPharma in a research note to investors on Tuesday. They now have a $42.00 price target on the stock. Separately, analysts at Ned Davis Research downgraded shares of ViroPharma from a “neutral” rating to a “sell” rating in a research note to investors on Monday, September 30th. Finally, analysts at Deutsche Bank downgraded shares of ViroPharma from a “buy” rating to a “hold” rating in a research note to investors on Thursday, September 19th. They now have a $43.00 price target on the stock, up previously from $38.00. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $37.96.
Shares of ViroPharma (NASDAQ:VPHM) traded down 2.14% during mid-day trading on Wednesday, hitting $38.86. 556,285 shares of the company’s stock traded hands. ViroPharma has a one year low of $22.12 and a one year high of $41.14. The stock’s 50-day moving average is $35.20 and its 200-day moving average is $29.83. The company’s market cap is $2.546 billion.
ViroPharma (NASDAQ:VPHM) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.15 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.14. The company had revenue of $104.00 million for the quarter, compared to the consensus estimate of $105.06 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. On average, analysts predict that ViroPharma will post $-0.78 earnings per share for the current fiscal year.
ViroPharma Incorporated (NASDAQ:VPHM) is an international biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.